title: Effects of repetitive administration of tianeptine, zinc hydroaspartate and electroconvulsive shock on the reactivity of 5-HT(7) receptors in rat hippocampus.
abstract: The influence of repeated administration of tianeptine, an atypical antidepressant, which was administered twice daily (10 mg/kg) for 14 days and zinc hydroaspartate, a compound exhibiting antidepressant-like activity, which was administered twice daily (65 mg/kg) for 14 days, and the effects of electroconvulsive shocks (ECS) delivered once daily for 10 days, were investigated ex vivo in rat hippocampal slices. Slices were prepared 2 days after the last session of treatment of animals, and spontaneous epileptiform bursts were recorded extracellularly from the CA3 area. 5-HT(7) receptor-mediated increase in bursting frequency was induced by bath application of of 5-carboxamidotryptamine (5-CT; 0.025-1 microM) in the presence of N-[2-[4-(2-methoxyphenyl)-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY 100635; 2 microM), an antagonist of the 5-HT(1A) receptor. The data indicate an enhancement of the excitatory effect of the activation of 5-HT(7) receptors after ECS repeated ten times, but not by a single ECS. Neither tianeptine nor zinc, administered for 14 days, altered the reactivity of 5-HT(7) receptors.
authors.affiliation: Department of Physiology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, PL 31-343 Kraków, Poland.
authors.forename: Patrycja
authors.initials: P
authors.lastname: Pitra
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Tokarski
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Grzegorzewska
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Hess
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000494:pharmacology*; D002413:Cations, Divalent; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004597:Electroshock; D004827:Epilepsy / Q000503:physiopathology; D006624:Hippocampus / Q000187:drug effects* / Q000503:physiopathology; D066298:In Vitro Techniques; D008297:Male; D010879:Piperazines / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011985:Receptors, Serotonin / Q000502:physiology*; D012701:Serotonin / Q000031:analogs & derivatives / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D013841:Thiazepines / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors; D015032:Zinc / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000929:Antidepressive Agents, Tricyclic; D002413:Cations, Divalent; D010879:Piperazines; D011725:Pyridines; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D013841:Thiazepines; C104425:serotonin 7 receptor; C050504:tianeptine; D012701:Serotonin; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide; C047087:5-carboxamidotryptamine; D015032:Zinc